Kura Oncology is poised for a significant stock rally, according to JPMorgan analyst Priyanka Grover, who initiated coverage with an overweight rating and a $30 year-end price target, implying 180% upside from Wednesday’s close of $10.71. Shares rose about 1% on Thursday. The bullish outlook hinges on Kura’s transition to a commercial-stage company following Komzifti’s FDA approval in November 2025 for adults with relapsed or refractory acute myeloid leukemia carrying a NPM1 mutation. Early sales of the once-daily pill show “aggressive physician adoption,” Grover noted. Net product revenue grew from $2.1 million in the final five weeks of 2025 to $9.1 million in Q2 2026. JPMorgan sees an opportunity to expand Komzifti to newly diagnosed patients, estimating roughly $1.5 billion in potential worldwide peak sales. Kura has “clear potential” to capture meaningful leukemia market share. Grover’s sum-of-the-parts analysis also values darlifarnib, an experimental drug blocking tumor growth signals, at $600 million in potential peak sales, calling it a “potential second oncology franchise” for the San Diego-based company. An April study showed that combining darlifarnib with cabozantinib demonstrated robust antitumor activity. JPMorgan said Kura shares have “significant upside potential” as clinical trials advance and the market recognizes opportunities from both treatments. Kura Oncology’s year-to-date performance is illustrated.
Also Read
- Dual UK-Iranian National Detained in Connection with RAF Fairford Security Incident
- Apple’s App Store May Face $10 B Revenue Hit from Meta’s Muse AI Agent, Analysts Warn
- Deemah Al-Yahya appointed member of UN panel on freedom of transit for landlocked developing countries
- Forgotten Island: A Bittersweet Tribute to the Filipino Diaspora
